| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
136,480,000 |
| Market
Cap: |
3.66(B) |
| Last
Volume: |
503,160 |
Avg
Vol: |
501,799 |
| 52
Week Range: |
$26.23 - $39.94 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P 400 MIDCAP |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Perrigo is a provider of over-the-counter health and wellness solutions that can be self-managed. Co.'s segments are as follows: Consumer Self-Care Americas, which is focused primarily on the sale of self-care products in categories including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements; Consumer Self-Care International, which develops, manufactures, markets, and distributes European consumer self-care brands in the upper respiratory, pain and sleep-aids, digestive health, vitamins, minerals and supplements; and Prescription Pharmaceuticals, which develops, manufactures, and markets a portfolio of generic prescription drugs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zilberfarb Ben-Zion |
Director |
– • – |
2010-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,130 |
7,486 |
|
- |
|
| Kunkle Gary K Jr |
Director |
– • – |
2010-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,130 |
21,031 |
|
- |
|
| Jandernoa Michael J |
Director |
– • – |
2010-11-09 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,170 |
1,684,399 |
|
- |
|
| Jandernoa Michael J |
Director |
– • – |
2010-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,130 |
6,245 |
|
- |
|
| Gottfried Ran |
Director |
– • – |
2010-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,130 |
9,986 |
|
- |
|
| Arkin Moshe |
Director |
– • – |
2010-11-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,600 |
87,181 |
|
- |
|
| Arkin Moshe |
Director |
– • – |
2010-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,130 |
88,781 |
|
- |
|
| Brlas Laurie |
Director |
– • – |
2010-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,130 |
16,558 |
|
- |
|
| Jandernoa Michael J |
Director |
– • – |
2010-10-27 |
4 |
GD |
$0.00 |
$0 |
I/I |
5,375 |
1,685,569 |
|
- |
|
| Lebel Refael |
EVP & GM Perrigo Israel |
• – – |
2010-09-01 |
4 |
S |
$58.21 |
$177,075 |
D/D |
(3,042) |
9,344 |
|
- |
|
| Yu Louis |
Senior VP Global Quality |
• – – |
2010-09-01 |
4 |
S |
$58.18 |
$96,807 |
D/D |
(1,664) |
5,490 |
|
- |
|
| Yu Louis |
Senior VP Global Quality |
• – – |
2010-09-01 |
4 |
OE |
$20.50 |
$34,112 |
D/D |
1,664 |
7,154 |
|
- |
|
| Jandernoa Michael J |
Director |
– • – |
2010-09-01 |
4 |
S |
$58.04 |
$615,979 |
D/D |
(10,613) |
5,115 |
|
- |
|
| Jandernoa Michael J |
Director |
– • – |
2010-09-01 |
4 |
OE |
$6.56 |
$69,648 |
D/D |
10,613 |
15,728 |
|
- |
|
| Shah Jatin |
Sr VP & Chief Scientific Offic |
• – – |
2010-09-01 |
4 |
S |
$57.99 |
$572,758 |
D/D |
(9,877) |
8,477 |
|
- |
|
| Shah Jatin |
Sr VP & Chief Scientific Offic |
• – – |
2010-09-01 |
4 |
OE |
$15.47 |
$239,698 |
D/D |
9,877 |
18,354 |
|
- |
|
| Farrington Thomas |
Senior VP and CIO |
• – – |
2010-09-01 |
4 |
S |
$57.81 |
$64,400 |
D/D |
(1,114) |
1,903 |
|
- |
|
| Farrington Thomas |
Senior VP and CIO |
• – – |
2010-09-01 |
4 |
OE |
$20.50 |
$22,837 |
D/D |
1,114 |
3,017 |
|
- |
|
| Hendrickson John T |
EVP Global Operations & Supply |
• – – |
2010-09-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
8,348 |
0 |
|
- |
|
| Kochan Sharon |
Executive VP U.S. Generics |
• – – |
2010-09-01 |
4 |
S |
$58.24 |
$209,664 |
D/D |
(3,600) |
7,542 |
|
- |
|
| Needham Jeffrey |
Sr. VP Commercial Business Dev |
• – – |
2010-08-31 |
4 |
S |
$57.21 |
$58,927 |
D/D |
(1,030) |
10,718 |
|
- |
|
| Stewart Michael Robert |
Sr. VP Global Human Resources |
• – – |
2010-08-31 |
4 |
S |
$57.50 |
$686,033 |
D/D |
(11,931) |
862 |
|
- |
|
| Stewart Michael Robert |
Sr. VP Global Human Resources |
• – – |
2010-08-31 |
4 |
OE |
$15.47 |
$173,086 |
D/D |
6,931 |
7,793 |
|
- |
|
| Kingma Todd W |
Executive VP, General Counsel |
• – – |
2010-08-31 |
4 |
S |
$57.21 |
$257,455 |
D/D |
(4,500) |
26,245 |
|
- |
|
| Shah Jatin |
Sr VP & Chief Scientific Offic |
• – – |
2010-08-30 |
4 |
D |
$57.62 |
$93,805 |
D/D |
(1,628) |
8,477 |
|
- |
|
1400 Records found
|
|
Page 25 of 56 |
|
|
0.54 (1.97%) 
